Patents Represented by Law Firm NeXstar Pharmaceuticals, Inc.
  • Method of making liposomes with improved stability during drying
    Patent number: 5817334
    Abstract: A composition and method are provided for the making of cholesterol containing phospholipid liposomes such that when dried and then reconstituted, the liposomes retain their structure and size distribution as well as substantially all of the material that was originally encapsulated, and they behave biologically in a normal fashion. The cryoprotective agents are used in the aqueous medium to hydrate the phospholipid(s) and are a combination of at least one sugar and at least one protein, polypeptide, and/or oligopeptide.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 6, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Paul G. Schmidt, Gary Fujii
  • Antibiotic formulation and use for drug resistant infections
    Patent number: 5759571
    Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: June 2, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
  • Antibiotic formulation and use for drug resistant infections
    Patent number: 5756120
    Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 26, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Evan M. Hersch, Eskild A. Petersen, Richard T. Proffitt, Kevin R. Bracken, Su-Ming Chiang
  • Antibiotic formulation and use for drug resistant infections
    Patent number: 5756121
    Abstract: A liposomal aminoglycoside formulation comprising a neutral lipid, a negatively charged lipids and a sterol. The formulation contains unilamellar vesicles having an average size below 100 nm. A process of making liposomes containing an aminoglycoside is provided where the hydration temperature is significantly below the transition temperature of the formulation. A method for the treatment of drug susceptible and drug resistant bacteria.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 26, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventor: Kevin R. Bracken
  • Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
    Patent number: 5714163
    Abstract: A liposome formulation containing a Vinca Alkaloid and an ion in an aqueous phase of the liposome. The liposomes also comprise distearoylphosphatidyl choline, cholestrol and disteraroylphosphatidylglycerol. A method for enhancing the efficacy and tumor targeting properties of liposomal vinca alkaloid formulations containing unilamellar vesicles.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: February 3, 1998
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Eric Forssen, Gerry Cox, Dennis Hair
  • Blood stable liposomal cyclosporin formulations
    Patent number: 5693336
    Abstract: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratio of about 28:1:3:1 to 40:1:3:1 which are stable in mammalian blood.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 2, 1997
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventor: Karen L. Moynihan
  • Pharmaceutical formulation and process
    Patent number: 5688525
    Abstract: A process for preparing a liposomal cyclosporin therapeutic formulation, which comprises dissolving a combination of a neutral and negatively charged phospholipid and a cyclosporin in an organic solvent; drying the solution to form a solid phase, and hydrating the solid phase in an aqueous solution having a pH ranging from 7.5 to 9.5.
    Type: Grant
    Filed: June 30, 1993
    Date of Patent: November 18, 1997
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Jill P. Adler-Moore, William A. Ernst
  • Pharmaceutical formulation and process
    Patent number: 5670166
    Abstract: A process for preparing a liposomal cyclosporin therapeutic formulation, which comprises dissolving a combination of a neutral and negatively charged phospholipid and a cyclosporin in an organic solvent; drying the solution to form a solid phase, and hydrating the solid phase in an aqueous solution having a pH ranging from 7.5 to 9.5.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 23, 1997
    Assignee: NeXstar Pharmaceuticals
    Inventors: Jill P. Adler-Moore, William A. Ernst
  • Inhibition of aggregation of drug containing particles
    Patent number: 5665381
    Abstract: A method and composition for the prevention of aggregation of liposomes which include a multivalent anion disposed on the outer surface thereof comprises the addition of a divalent cation to the external aqueous phase.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 9, 1997
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Crispin G. S. Eley, Eric A. Forssen
  • Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
    Patent number: 5656287
    Abstract: An improved liposomal cyclosporin therapeutic formulation, comprising phosphatidylcholine, cholesterol, dimyristoylphosphatidylglycerol and a cyclosporin in a mole ratios of about 21:0.5:3:1 to 21:1.5:3:1 and 24:0.5:3:1 to about 24:1.5:3:1. The formulations are useful as immunosuppressive agents and enhancers of antineoplastic agents in drug resistant cancer cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 12, 1997
    Assignee: NeXstar Pharmaceuticals, Inc.
    Inventors: Jill Adler-Moore, Su-Ming Chiang